Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

VerifyNow for å optimalisere blodplatehemming ved koronar akutt syndrom (VERONICA)

21. september 2026 oppdatert av: Fundación EPIC

VerifyNow for å optimalisere blodplatehemming ved koronar akutt syndrom (VERONICA-prøven)

The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).

Studieoversikt

Detaljert beskrivelse

Clinical practice guidelines recommend the use of double anti-aggregation with acetylsalicylic acid and a P2Y12 receptor inhibitor (P2Y12 i) in acute coronary syndrome (ACS) and in the choice of the latter it is very important to consider two opposing risks, Ischemia and hemorrhage. In the era of clopidogrel, platelet function tests (PFT) attempted to determine which patients were at risk of thrombotic events, but after the publication of 3 randomized studies, the absence of benefit from the use of PFT was proven except in very selected cases. The TOPIC trial opened the door to the descaling strategy of P2Y12 i with a decrease in hemorrhagic events without increasing ischemic complications. In that study, where the randomization was not based on PFT, it was demonstrated that there is a subgroup of patients who with prasugrel and ticagrelor pose an excessive level of antiaggregation and carry a high rate of complications, as high as 33 % in the net clinical end-point of ischemia and bleeding BARC ≥ 2 at 1 year. Based on that data, the recently published guidelines of the non-ST acute coronary syndrome of the European Society of Cardiology recommend with class IIB that de-escalation of P2Y12 i maybe considered an alternative strategy, especially in ACS patients deemed unsuitable for potent platelet inhibition. De-escalation may be done based on clinical judgment, or guided by platelet function testing, or CYP2C19 genotyping depending on the patient's risk profile and availability of respective assays. In VERONICA, The researchers try to demonstrate with the current study the usefulness of PFT to diagnose patients with excessive level of antiaggregation and to see if in them a descaling strategy similar to that of TOPIC could be associated with a decrease in the combined ischemia and hemorrhage events. We propose a prospective, randomized and multicentre trial in patients with ACS who have been treated with acetylsalicylic acid (AAS) + ticagrelor or prasugrel. After 1 month of discharge, antiaggregation measurement will be carried out with the VerifyNow® device (Werfen, Spain) and those with PRU ≤30 will be randomized 1:1 to continue with ticagrelor or prasugrel(control branch) vs. de-escalation to clopidogrel (intervention branch) for the remaining 11 months. The primary end-point will be the rate of the combined net clinical benefit consisting of cardiovascular death, nonfatal acute myocardial infarction (AMI), nonfatal stroke and bleeding BARC ≥2 at 12 months. The total number of randomized patients will be 634 and there will be subgroup analysis of the primary end-point by diabetes, type of acute coronary syndrome or type of drug (ticagrelor or prasugrel).

Studietype

Intervensjonell

Registrering (Faktiske)

637

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Albacete, Spania, 02006
        • Hospital General Universitario de Albacete
      • Barcelona, Spania, 08003
        • Hospital Del Mar
      • Barcelona, Spania, 08035
        • Hospital Universitari Vall D Hebron
      • Ciudad Real, Spania, 13005
        • Hospital General Universitario de Ciudad Real
      • Cáceres, Spania, 10003
        • Hospital San Pedro de Alcantara
      • Galdakao, Spania, 48960
        • Hospital Universitario de Galdakao-Usansolo
      • Gijón, Spania, 33394
        • Hospital Universitario de Cabueñes
      • Granada, Spania, 18014
        • Hospital Universitario Virgen de Las Nieves
      • Huelva, Spania, 21005
        • Hospital Universitario Juan Ramon Jimenez
      • L'Hospitalet de Llobregat, Spania, 08907
        • Hospital Universitari de Bellvitge
      • León, Spania, 24080
        • Hospital de León
      • Lugo, Spania, 27003
        • Hospital Universitario Lucus Agusti
      • Málaga, Spania, 29010
        • Hospital Universitario Regional de Malaga
      • Salamanca, Spania, 37007
        • Hospital Universitario de Salamanca
      • Santander, Spania, 39008
        • Hospital Universitario Marques de Valdecilla
      • Valladolid, Spania, 47003
        • Hospital Clinico Universitario de Valladolid
      • Zaragoza, Spania, 50009
        • Hospital Universitario Miguel Servet
      • Zaragoza, Spania, 50009
        • Hospital Universitario Lozano Blesa
    • Murcia
      • El Palmar, Murcia, Spania, 30120
        • Hospital Universitario Virgen de La Arrixaca

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with age 18 years or above.
  • Patient is able to understand the nature of study and has provided written informed consent.
  • Patients with Acute Coronary Syndrome and who underwent PCI during the admission, who have been discharged on double. antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel.

Exclusion Criteria:

  • Patients with history of intracranial bleeding.
  • Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel.
  • Patients with major ischemic or hemorrhagic events during the first month.
  • Patients with Thrombocytopenia <50,000 /µL.
  • Patients with permanent oral anticoagulation.
  • Patient is pregnant or breast feeding.
  • Patients with impossibility to complete 1 year of follow-up.
  • Patient´s life-expectancy is less than 24 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )

Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.

Clopidogrel during 11 months

Annen: VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )

Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.

non-intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Net Adverse Cardiac Events (NACE)
Tidsramme: 12 months

Net Adverse Cardiac Events, defined as a composite of: death from vascular causes (death from cardiovascular causes or cerebrovascular causes and any death without another known cause), non fatal MI, or non fatal stroke, Bleeding BARC type ≥ 2.

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Death (Cardiovascular)
Tidsramme: 12 months

Death (Cardiovascular)

12 months
Incidence of Death
Tidsramme: 12 months

Death

12 months
Incidence of Non fatal Myocardial Infarction (MI)
Tidsramme: 12 months

Non fatal Myocardial Infarction

12 months
Incidence of Stroke
Tidsramme: 12 months

Ischemic Stroke

12 months
Incidence of Thrombosis in target lesion
Tidsramme: 12 months

Stent Thrombosis in target lesion

12 months
Incidence of revascularization on target lesion
Tidsramme: 12 months

New revascularization on target lesion

12 months
Incidence of (BARC criteria ≥ 2)
Tidsramme: 12 months

Bleeding (BARC criteria ≥ 2)

12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juli 2021

Primær fullføring (Faktiske)

29. juli 2026

Studiet fullført (Faktiske)

5. august 2026

Datoer for studieregistrering

Først innsendt

20. september 2020

Først innsendt som oppfylte QC-kriteriene

29. november 2020

Først lagt ut (Faktiske)

4. desember 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere